NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
Clinical Trials
16 trialsNCT02158858 2025-10-08
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT04669210 2025-07-04
PTCyRuxo
St. Petersburg State Pavlov Medical University
Phase 2 Completed
NCT02257138 2025-06-08
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01895842 2025-02-28
Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05663827 2024-03-05
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Chang Gung Memorial Hospital
Phase 3 Completed
NCT04055844 2023-11-07
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01776723 2022-09-22
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01702064 2021-01-05
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02092324 2020-11-16
Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01914484 2020-11-02
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
University Health Network, Toronto
Phase 1/2 Completed
NCT01369498 2020-07-01
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Gilead Sciences
Phase 2 Completed
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02253277 2019-05-01
CoRNea
Novartis
Phase 1 Completed
NCT02015208 2016-09-26
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
Sunnybrook Health Sciences Centre
Phase 1/2 Completed
NCT01164163 2014-10-23
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
Phase 1 Completed